Stellar Biotechnologies (OTCQB: SBOTF) (TSX-V: KLH), a leading manufacturer of Keyhole Limpet Hemocyanin (“KLH”) protein for generation of antibody and cell-mediated immune responses against disease indications, has received approval for its common shares to begin trading on The NASDAQ Capital Market as of November 5, 2015, under the symbol “SBOT.”
“This is a significant milestone for Stellar and an important step in our corporate growth,” Frank Oakes, president, CEO and chairman, of Stellar stated in the news release. “We anticipate that the listing of our shares on NASDAQ will raise our visibility within the investment community and with institutional investors, and will offer our shareholders an opportunity for increased liquidity. This approval comes at an important time for Stellar, as evidenced by our recently announced plan to expand manufacturing capacity to meet growing demand for KLH protein in immunotherapy. We look forward to sharing our future achievements with investors, customers, and collaborators.”
In recognition of the achievement, Nasdaq has invited Stellar to ring the Nasdaq Closing Bell tomorrow afternoon, the first day of the company’s trade on the exchange. Oakes and members of Stellar’s management team will participate in the Nasdaq closing ceremony on Thursday, November 5, 2015, at 4 p.m. ET at the Nasdaq MarketSite in New York City. The event will be broadcast live via Nasdaq’s livestream portal at http://livestream.com/nasdaq/live.
For more information visit www.stellarbiotechnologies.com
